Search Result

Results for "

MDM2+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (13) Autophagy (4) Bcl-2 Family (1) c-Myc (1) Caspase (2) Cyclin G-associated Kinase (GAK) (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (2) E1/E2/E3 Enzyme (17) MDM-2/p53 (36) NF-κB (3) PROTACs (1) Reference Standards (3) Topoisomerase (2)
By Research Areas:	Cancer (38)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50696

Nutlin-3 40+ Cited Publications	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 is a commercial available *p53-MDM2* inhibitor, with K_i of 90 nM.

HY-10029

Nutlin-3a Maximum Cited Publications 66 Publications Verification Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas ^[2].

HY-101266

Milademetan 5 Publications Verification DS-3032	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) is a specific and orally active *MDM2* inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis ^[2].

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase *MDM-2* inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research ^[2] .

HY-15954

NVP-CGM097 3 Publications Verification CGM097	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
NVP-CGM097 is a potent and selective *MDM2* inhibitor with IC₅₀ of 1.7±0.1 nM for *hMDM2*.

HY-15335

Nutlin-3b 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3b, the inactive form of Nutlin-3 (HY-50696), is a *p53/MDM2** inhibitor* with an IC₅₀ of 13.6 μM. Nutlin-3b is 150 times less potent in binding to *MDM2* than Nutlin-3a (HY-10029). Nutlin-3b is promising for research of cancers ^[2] .

HY-16999

RO8994	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
RO8994 (Compound 4) is an orally active, highly potent and selective spiroindolinone *p53-MDM2* inhibitor with an IC₅₀ value of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). RO8994 induces up-regulation of p53 expression and Apoptosis in wild-type p53 cancer cells. RO8994 also inhibits tumor growth in the tumor xenograft model ^[2] .

HY-15954B

NVP-CGM097 sulfate 3 Publications Verification CGM097 sulfate	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
NVP-CGM097 sulfate is a potent and selective *MDM2* inhibitor with IC₅₀ of 1.7±0.1 nM for *hMDM2*.

HY-101266B

Milademetan tosylate hydrate 5 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active *MDM2* inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis ^[2].

HY-128843

*PROTAC MDM2* Degrader-4**	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-4 is a *MDM2* degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase .

HY-133760

MI-888	MDM-2/p53	Cancer
MI-888 is an orally active *MDM2* inhibitor with a K_i of 0.44 nM. MI-888 can inhibit the *MDM2-p53* interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .

HY-10029A

(Rac)-Nutlin-3 (Rac)-Rebemadlin	MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme	Cancer
(Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). (Rac)-Nutlin-3 inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas ^[2].

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-12734

AM-8735	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
AM-8735 is a potent and selective *MDM2* inhibitor with an IC₅₀ of 25 nM.

HY-50696R

Nutlin-3 (Standard)	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 (Standard) is the analytical standard of Nutlin-3. This product is intended for research and analytical applications. Nutlin-3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.

HY-178036

ZM484	MDM-2/p53 Topoisomerase Bcl-2 Family Caspase Cyclin G-associated Kinase (GAK)	Cancer
ZM484 is a potent dual *p53-MDM2/TOP1* inhibitor that exhibits antiproliferative and antitumor activity both in vitro and in vivo. ZM484 effectively upregulates p53 and MDM2 proteins and maintains TOP1 inhibitory activity by the release of camptothecin (CPT) and a potent p53-MDM2 inhibitor. ZM484 induces cell cycle arrest and apoptosis by regulating the expression of key apoptosis- and cycle-related proteins, including caspase-3, *Bcl-2, and Cyclin B1*. ZM484 can be used for colorectal cancer research .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits *MDM2*-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-12737

AM-6761	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
AM-6761 is a potent *MDM2* inhibitor with an IC₅₀ of 0.1 nM.

HY-139458

MDM2-IN-21	MDM-2/p53	Cancer
MDM2-IN-21 is a potent *MDM2* inhibitor. MDM2-IN-21 can be used for the research of cancer .

HY-15954A

NVP-CGM097 (stereoisomer) CGM097 stereoisomer	Drug Isomer	Others
NVP-CGM097 (stereoisomer) is a stereoisomer of NVP-CGM097, with no special bioactivity. NVP-CGM097 is a potent and selective MDM2 inhibitor.

HY-W598456

Brigimadlin intermediate-1	Drug Intermediate	Cancer
Brigimadlin intermediate-1 is an intermediate of the E3 ubiquitin protein ligase *MDM-2* inhibitor Brigimadlin (HY-152859) and can be used to synthesize Antibody-Drug Conjugates (ADCs) .

HY-12579

RO 2468	MDM-2/p53	Cancer
RO 2468 is a potent, orally active and selective *p53-MDM2* inhibitor. RO 2468 has anti-proliferative active. RO 2468 suppresses c growth in SJSA1 osteosarcoma models without obvious toxicity .

HY-121893

p53-MDM2-IN-3	MDM-2/p53 NF-κB	Cancer
p53-MDM2-IN-3 (Compound 5s) is an orally active *p53-MDM2* inhibitor with a K_i value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .

HY-116052

p53-MDM2-IN-2	MDM-2/p53 NF-κB	Cancer
p53-MDM2-IN-2 (Compound 5q) is an orally active *p53-MDM2* inhibitor with a K_i value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .

HY-162247

MDM2-IN-26	MDM-2/p53	Cancer
MDM2-IN-26 (compound A3) is an *MDM2* inhibitor that can activate the tumor suppressor function of p53 by blocking the interaction between MDM2 and p53 (MDM2 is the main negative regulator of p53). MDM2-IN-26 can be used for cancer research .

HY-163083

JN122	MDM-2/p53 Apoptosis	Cancer
JN122, a spiroindoline-containing molecule, is a MDM2 inhibitor. JN122 Inhibits MDM2/p53 protein–protein interaction and exerts robust in vivo antitumor efficacy. JN122 has antiproliferative activity in HCT-116 cells and HEK-293 cells with IC₅₀ values of 39.6 nM and 4.28μM, respectively. JN122 can promote activation of p53 and its target genes, inhibited cell cycle progression, and induced cell apoptosis .

HY-163661

p53-MDM2-IN-5	Apoptosis Autophagy MDM-2/p53	Cancer
p53-MDM2-IN-5 (compound 5a) is a potent *p53-MDM2* inhibitor. p53-MDM2-IN-5 induces apoptosis, autophagy and DNA damage. p53-MDM2-IN-5 induces cell cycle arrest at S and G2/M phases. p53-MDM2-IN-5 shows anti-tumor activity .

HY-162927

p53-MDM2-IN-6	MDM-2/p53 Apoptosis	Cancer
p53-MDM2-IN-6 (Compound 10a), a LSM-83177 hydrazone analog, is a potent *p53-MDM2* inhibitor with an IC₅₀ value of 11.08 µg/mL. p53-MDM2-IN-6 arrests the cell cycle in the S phase and induces early and late Apoptosis with antiproliferative activity against HT29 cell lines with an IC₅₀ value of 10.44 µg/mL. p53-MDM2-IN-6 inhibits p53-MDM2 interaction with increment in p-53 level and decrease the expression of GST enzymes. p53-MDM2-IN-6 is promising for research of colorectal cancer .

HY-152859A

Brigimadlin enantiomer BI 907828 enantiomer	Drug Isomer	Cancer
Brigimadlin (BI 907828) enantiomer is the Brigimadlin (HY-152859) enantiomer. Brigimadlin is an MDM2 inhibitor with anti-cancer activity .

HY-18658B

Siremadlin succinate NVP-HDM201 succinate; HDM201 succinate	MDM-2/p53	Cancer
Siremadlin (NVP-HDM201) succinate is an *MDM2* inhibitor and cell cycle regulator. Siremadlin succinate blocks the p53-binding pocket of MDM2, inhibits MDM2-mediated ubiquitination and degradation of p53, thereby activating the p53 pathway in p53 wild-type cells. Siremadlin succinate can be used in the research of cutaneous melanoma .

HY-15954C

(R)-NVP-CGM097 (R)-CGM097	MDM-2/p53	Cancer
(R)-NVP-CGM097 is the R-enantiomer of NVP-CGM097 (HY-15954). NVP-CGM097 is a potent and selective *MDM2* inhibitor with an IC₅₀ of 1.7 nM for hMDM2 .

HY-101266R

Milademetan (Standard) DS-3032 (Standard)	MDM-2/p53 Reference Standards E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (Standard) is the analytical standard of Milademetan (HY-101266). This product is intended for research and analytical applications. Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis ^[2].

HY-101266BR

Milademetan tosylate hydrate (Standard) DS-3032b (Standard); DS-3032 tosylate hydrate (Standard)	MDM-2/p53 Reference Standards E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (tosylate hydrate) (Standard) is the analytical standard of Milademetan (tosylate hydrate) (HY-101266B). This product is intended for research and analytical applications. Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis ^[2].

HY-180331

NVP-CFC218	MDM-2/p53	Cancer
NVP-CFC218 is a selective TP53-MDM2 inhibitor with a structure and biochemical profile similar to NVP-CGM097 (HY-15954) (IC₅₀ of 1.6 nM: displacing the p53 peptide from the surface of HDM2). It is used to analyze pharmacological sensitivity in cell lines and is also applicable in cancer research ^[1] ^[2].

HY-168606A

p53-MDM2-IN-7 hydrochloride	MDM-2/p53	Cancer
p53-MDM2-IN-7 (compound 6d) (hydrochloride) is a *p53-MDM2* inhibitor. p53-MDM2-IN-7 has an IC₅₀ value of 8.13 μM against A549 cells. p53-MDM2-IN-7 can be used in anti-cancer research .

HY-182746

RG7388-PEG3-Click-F	MDM-2/p53 Drug Derivative	Cancer
RG7388-PEG3-Click-F is a fluorinated analog of the *MDM2* inhibitor RG7388 (HY-15676), with an IC₅₀ of 16.8 nM against *MDM2. [ ¹⁸F]RG7388-PEG3-Click-F exhibits high uptake and specificity in MDM2-expressing* myeloma cells, and can be used for non-invasive assessment of MDM2 protein expression levels in tumors .

HY-115797

LQFM030	MDM-2/p53 Caspase c-Myc Apoptosis NF-κB	Cancer
LQFM030 is a novel small molecule *MDM2* inhibitor. LQFM030 exhibits concentration dependent cytotoxicity in K562 cells (IC₅₀ = 0.28 mM). LQFM030 induces cell apoptosis through G0/G1 phase cell cycle arrest and increased Caspase activity. LQFM030 downregulates the mRNA expression of MDM2, MDMX, p73, MYC, and NF-κB. LQFM030 is commonly used in research on cancers such as leukemia .

HY-180508

MDM2-IN-27	MDM-2/p53 Topoisomerase	Cancer
MDM2-IN-27 (Compound 20k) is an *MDM2* inhibitor. MDM2-IN-27 can effectively block the inhibitory effect of MDM2 on p53, thereby activating the p53 pathway. MDM2-IN-27 has a certain topoisomerase I inhibitory activity and has a very weak inhibitory effect on topoisomerase IIα. MDM2-IN-27 exhibits significant anti-proliferative activity against breast cancer, colon cancer, and cutaneous squamous cell carcinoma .

HY-10029R

Nutlin-3a (Standard) Rebemadlin (Standard)	MDM-2/p53 Reference Standards E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Standard) is the analytical standard of Nutlin-3a (HY-10029). This product is intended for research and analytical applications. Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

MDM2+inhibitor

Inhibitors & Agonists